These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27108094)

  • 1. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.
    Endres BT; Bassères E; Memariani A; Chang L; Alam MJ; Vickers RJ; Kakadiaris IA; Garey KW
    Anaerobe; 2016 Aug; 40():10-4. PubMed ID: 27108094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.
    Endres B; Bassères E; Rashid T; Chang L; Alam MJ; Garey KW
    J Vis Exp; 2017 May; (123):. PubMed ID: 28570548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
    J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
    Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
    Skinner K; Birchall S; Corbett D; Thommes P; Locher HH
    J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.
    Goldstein EJ; Citron DM; Tyrrell KL; Warren YA
    Anaerobe; 2010 Jun; 16(3):220-2. PubMed ID: 20044011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.
    Bassères E; Endres BT; Khaleduzzaman M; Miraftabi F; Alam MJ; Vickers RJ; Garey KW
    J Antimicrob Chemother; 2016 May; 71(5):1245-51. PubMed ID: 26895772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
    Sachdeva M; Leeds JA
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1252-7. PubMed ID: 25512411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.
    Odenholt I; Walder M; Wullt M
    Chemotherapy; 2007; 53(4):267-74. PubMed ID: 17595541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.